文献速递免疫规划

黄热病疫苗加强接种免疫应答微弱与预存抗体相关

Minimal immune response to booster vaccination against Yellow Fever associated with pre-existing antibodies.
PubMed 文献 · Vaccine · 2020-01-31

在瑞士开展纵向黄热病YF-17D疫苗接种研究,比较初种与加强接种的体液、固有及适应性细胞免疫应答。加强接种应答较初种大幅降低,基线中和抗体与疫苗病毒复制及加强后免疫应答呈负相关,提示存在中和抗体时加强接种可能无主要免疫学效应。

要点

  • 加强接种的固有与适应性免疫应答较初种大幅降低。
  • 基线中和抗体与疫苗病毒复制及加强后免疫应答呈负相关。
  • 存在中和抗体时加强接种可能无主要免疫学效应。

核心结论

  • 加强接种的免疫应答较初种大幅降低,基线中和抗体与疫苗病毒复制及加强后应答呈负相关。
  • 存在中和抗体时加强接种可能无主要免疫学效应。
  • 研究人群为非流行区健康成人,流行区加强接种需求须基于额外流行病学与公共卫生考量评估。

研究设计与样本

  • 在瑞士开展的纵向YF-17D疫苗接种研究,比较初种与加强接种。
  • 检测体液、固有及适应性细胞免疫应答。
  • 研究人群为非流行区健康成人。

主要发现

  • 初种引发强烈的固有与适应性免疫应答,而加强接种应答大幅降低。
  • 基线中和抗体与疫苗病毒复制呈负相关。
  • 基线中和抗体与加强后免疫应答呈负相关。

局限性

  • 研究人群为非流行区健康成人,流行区加强接种需求须基于额外流行病学与公共卫生考量评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ever since its development in the 1930's, the live-attenuated Yellow Fever virus vaccine YF-17D has been highly effective. Despite the increasing knowledge on the immune biology of the YF-17D vaccine, most studies have focused only on a few types of immune cells and pathways or mainly on the primary adaptive immune response to YF-17D vaccination. Here, we examined humoral, innate and adaptive cellular responses in a longitudinal YF-17D vaccination study in Switzerland, comparing both primary and booster vaccination. In contrast to the strong innate and adaptive immune response to the primary vaccination, we find that the response to boosting is much reduced. Our data show an inverse association of neutralizing antibodies at baseline with vaccine virus replication and with the immune response upon boosting. These results suggest that booster vaccination may not have major immunological effects when neutralizing antibodies are present. Importantly, our study population was healthy adults in a non-endemic country and ultimately booster vaccine requirement must be assessed based on additional epidemiological and public health considerations in endemic areas.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Bovay A, Nassiri S, Maby-El Hajjami H, et al. Minimal immune response to booster vaccination against Yellow Fever associated with pre-existing antibodies. Vaccine. 2020. PMID: 32008879. doi:10.1016/j.vaccine.2020.01.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。